Report #2863356

Received Oct 6, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 89 yrs
State: PA
Recovered: Unknown
Vaccinated: Sep 19, 2025
Onset: Sep 19, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	3EG9B	IM / RA

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

first dose of Shingrix vaccine during the year 2024 and received today the 2nd dose of Shingrix in her right arm; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 89-year-old female patient who received Herpes zoster (Shingrix) (batch number 3EG9B, expiry date 02-MAY-2027) for prophylaxis. Previously administered products included Shingrix (1st dose received on an unknown date in 2024). On 19-SEP-2025, the patient received the 2nd dose of Shingrix (intramuscular, right arm) .5 ml. On 19-SEP-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: first dose of Shingrix vaccine during the year 2024 and received today the 2nd dose of Shingrix in her right arm). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 19-SEP-2025 The reporter inquired if the patient needed a booster.